Treatment of aggressive recurrent meningiomas: spinning towards peptide receptor radionuclide therapy
- 40 Downloads
With a worldwide incidence of 45,000 cases, meningioma is the most common nonglial primary intracranial tumour. Although the tumour is often associated with indolent behaviour, in many patients it shows aggressive features and is associated with poor outcomes. After complete resection, the 5-year recurrence rates for grade I (benign), grade II (atypical) and grade III (anaplastic) tumours have been estimated to be 5%, 40% and 80%, respectively [1, 2]. Very few treatment options are available at this stage. The progression-free survival (PFS) in patients with aggressive recurrent meningiomas is less than 30% at 6 months, while the median overall survival is 3 years in patients with grade III tumour . It is therefore of major importance to develop new treatment options.
In recent years, peptide receptor radionuclide therapy (PRRT) with somatostatin analogues (SSAs) has become increasingly important in the treatment of patients with tumours expressing somatostatin receptor (SST),...
This work was conducted in the framework of DHU-Imaging thanks to the support of the A*MIDEX project (no. ANR-11-IDEX-0001-02) (Investissements d’Avenir French Government programme, managed by the French National Research Agency, ANR).
Compliance with ethical standards
Conflicts of interest
This article does not describe any studies with human participants performed by any of the authors.
- 6.Soto-Montenegro ML, Peña-Zalbidea S, Mateos-Pérez JM, Oteo M, Romero E, Morcillo M, et al. Meningiomas: a comparative study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for molecular imaging in mice. PLoS One. 2014;9:e111624. https://doi.org/10.1371/journal.pone.0111624.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Marincek N, Radojewski P, Dumont RA, Brunner P, Müller-Brand J, Maecke HR, et al. Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial. J Nucl Med. 2015;56:171–6. https://doi.org/10.2967/jnumed.114.147256.CrossRefPubMedGoogle Scholar
- 12.Seystahl K, Stoecklein V, Schüller U, Rushing E, Nicolas G, Schäfer N, et al. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake. Neuro Oncol. 2016;18:1538–47. https://doi.org/10.1093/neuonc/now060.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Kreissl MC, Hänscheid H, Löhr M, Verburg FA, Schiller M, Lassmann M, et al. Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Radiat Oncol. 2012;7:99. https://doi.org/10.1186/1748-717X-7-99.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Cremonesi M, Ferrari ME, Bodei L, Chiesa C, Sarnelli A, Garibaldi C, et al. Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning. Eur J Nucl Med Mol Imaging. 2018;45:2426–41. https://doi.org/10.1007/s00259-018-4044-x.CrossRefPubMedGoogle Scholar
- 18.Sundlöv A, Sjögreen-Gleisner K, Svensson J, Ljungberg M, Olsson T, Bernhardt P, et al. Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017;44:1480–9. https://doi.org/10.1007/s00259-017-3678-4.CrossRefPubMedPubMedCentralGoogle Scholar